FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model

OBJECTIVE: We wanted to investigate the feasibility of using FDG-PET for evaluating the antitumor effect of intraarterial administration of a hexokinase II inhibitor, 3-bromopyruvate (3-BrPA), in a rabbit VX2 liver tumor model. MATERIALS AND METHODS: VX2 carcinoma was grown in the livers of ten rabbits. Two weeks later, liver CT was performed to confirm appropriate tumor growth for the experiment. After tumor volume-matched grouping of the rabbits, transcatheter intraarterial administration of 3-BrPA was performed (1 mM and 5 mM in five animals each, respectively). FDG-PET scan was performed the day before, immediately after and a week after 3-BrPA administration. FDG uptake was semiquantified by measuring the standardized uptake value (SUV). A week after treatment, the experimental animals were sacrificed and the necrosis rates of the tumors were calculated based on the histopathology. RESULTS: The SUV of the VX2 tumors before treatment (3.87+/-1.51 [mean+/-SD]) was significantly higher than that of nontumorous liver parenchyma (1.72+/-0.34) (p < 0.0001, Mann-Whitney U test). The SUV was significantly decreased immediately after 3-BrPA administration (2.05+/-1.21) (p = 0.002, Wilcoxon signed rank test). On the one-week follow up PET scan, the FDG uptake remained significantly lower (SUV 1.41+/-0.73) than that before treatment (p = 0.002), although three out of ten animals showed a slightly increasing tendency for the FDG uptake. The tumor necrosis rate ranged from 50.00% to 99.90% (85.48%+/-15.87). There was no significant correlation between the SUV or the SUV decrease rate and the tumor necrosis rate in that range. CONCLUSION: Even though FDG-PET cannot exactly reflect the tumor necrosis rate, FDG-PET is a useful modality for the early assessment of the antitumor effect of intraarterial administration of 3-BrPA in VX2 liver tumor

The Temperature-Composition Phase Diagram and Mesophase Structure Characterization of the Monoolein/Water System

The temperature-composition phase diagram of monoolein in water was constructed using X-ray diffraction in the range of $0~^\circ{\rm C}$ to $104~^\circ{\rm C}$ and 0% (w/w) to 47% (w/w) water in the heating direction. The phases identified in this system include the lamellar crystalline (L$_{\rm c}$) phase, the lamellar liquid crystalline (L$_{\alpha}$) phase, the fluid isotropic (FI) phase, two inverted cubic phases (Q$^{230}$, Ia3d; Q$^{224}$, Pn3m), and the inverted hexagonal (H$_{\rm II}$) phase. The overall features of the monoolein/water phase diagram reported herein match those of existing phase diagrams for this system. There are some important differences, however. Accordingly, every effort has been taken to ensure that the current phase diagram represents equilibrium behavior and that the assorted phase boundaries have been determined accurately. The interpreted phase diagram is based on close to 400 discrete measurements in temperature-composition space recorded as a function of temperature in $5~^\circ{\rm C}$ increments ($3~^\circ{\rm C}$ in the H$_{\rm II}$ phase) and of composition in 2% (w/w) water increments on average. The various mesophases have been characterized structurally as a function of temperature and hydration, and the corresponding thermal and composition expansion coefficients are reported. These and related data show that the average radius of water channels in the fully hydrated bicontinuous cubic Pn3m phase is remarkably sensitive to temperature and to monoacylglycerol chain identity

Cross-Protective Immunity of Mice Induced by Oral Immunization with Pneumococcal Surface Adhesin A Encapsulated in Microspheres

The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection